Anastrozole Tablet, Coated
Product Images NDC 60687-112

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 60687-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

883d1c11 Aa54 57c7 E053 2995a90a6151

Anastrozole 1 mg coated oral tablet. The image shows a round, white tablet with the imprint "A7" on one side and a plain surface on the other. This tablet is labeled by American Health Packaging.*

FDA Label Image

Blister

Anastrozole 1 mg coated tablet labels printed in multiple duplicates on a sheet. Each label shows the product name, strength, dosage form, a barcode, and the labeler American Health Packaging with location Columbus, Ohio 43217. Expiry date and lot number placeholders are also visible.*

FDA Label Image

Carton

Anastrozole 1 mg coated tablets in a package of 30 tablets (3 blister packs of 10). The label shows it is a prescription drug by American Health Packaging, NDC 60687-112. Instructions include storage conditions and pharmacist dispensing requirements. The barcode and usage warnings are also visible.*

FDA Label Image

Figure 1

A survival curve chart displaying disease-free survival in months on the x-axis and the proportion of patients alive and disease-free on the y-axis. The chart compares two treatments, anastrozole and tamoxifen, with curves showing the proportion of patients remaining disease-free over 84 months. Patient counts at risk are listed for select time points for both treatments.*

FDA Label Image

Figure 2

A survival curve chart comparing disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The y-axis shows the proportion of patients alive and disease-free, and the x-axis represents months from 0 to 90. The graph includes the number of patients at risk for each treatment at various time points.*

FDA Label Image

Figure 3

A Kaplan-Meier survival curve chart comparing Anastrozole and Tamoxifen treatments over a 120-month period. The vertical axis shows the proportion event free, ranging from 0.50 to 1.00, while the horizontal axis represents time to event in months. Lines represent randomized treatment groups: solid for Anastrozole and dashed for Tamoxifen. Patient numbers at risk are listed below for specified months. The vertical axis is truncated for clarity.*

FDA Label Image

Figure 4

A Kaplan-Meier survival curve graph showing the proportion of patients event-free over time (months) comparing Anastrozole and Tamoxifen treatments. The x-axis represents time to event in months, and the y-axis represents the proportion event-free. Two curves illustrate outcomes for patients randomized to Anastrozole and Tamoxifen, with a table below indicating the number of patients at risk at various time points up to 120 months.*

FDA Label Image

Figure 5

A Kaplan-Meier survival curve chart comparing the proportion of patients with no disease progression over time (in months) for two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis represents the proportion not progressing. The chart includes the number of patients at risk at various time points.*

FDA Label Image

Figure 6

A line graph showing the proportion of patients not progressing over time in months for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The y-axis represents the proportion not progressing, while the x-axis shows time to progression in months from 0 to 40. A table below the graph indicates the number of patients at risk at various time points for each treatment.*

FDA Label Image

Structure

Chemical structure diagram of Anastrozole, showing its molecular components including nitrogen-containing rings and cyano groups attached to a benzene ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.